Treatment of rheumatoid arthritis with curcumin analog 3,5-bis(arylidene)-4-piperidone
Rheumatoid arthritis (RA) is an inflammatory disease. Curcumin can inhibit NF-κB and reduce the expression of inflammation-related genes. Aim: To evaluate the potential development of 6d in the clinical treatment of inflammatory diseases such as RA. Methods: Using a skeleton fusion strategy to synthesize curcumin analogues for 6d. This work evaluates anti-inflammatory activity by conducting anti-arthritis experiments (adjuvant-induced RA models) on rats. Western blot and ELISA were used to detect the expression of inflammatory-related proteins and cytokines. Molecular docking analysis confirmed the binding effect of 6d with active sites. Conclusion: 6d inhibits NF-κB has a protective effect on arthritis caused by RA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 15(2023), 22 vom: 06. Nov., Seite 2051-2064 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Wenxuan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3,5-Bis(arylidene)-4-piperidone derivatives |
|---|
| Anmerkungen: |
Date Completed 17.11.2023 Date Revised 17.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/fmc-2023-0119 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364214376 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364214376 | ||
| 003 | DE-627 | ||
| 005 | 20231226094950.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2023-0119 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1213.xml |
| 035 | |a (DE-627)NLM364214376 | ||
| 035 | |a (NLM)37929594 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Wenxuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of rheumatoid arthritis with curcumin analog 3,5-bis(arylidene)-4-piperidone |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.11.2023 | ||
| 500 | |a Date Revised 17.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Rheumatoid arthritis (RA) is an inflammatory disease. Curcumin can inhibit NF-κB and reduce the expression of inflammation-related genes. Aim: To evaluate the potential development of 6d in the clinical treatment of inflammatory diseases such as RA. Methods: Using a skeleton fusion strategy to synthesize curcumin analogues for 6d. This work evaluates anti-inflammatory activity by conducting anti-arthritis experiments (adjuvant-induced RA models) on rats. Western blot and ELISA were used to detect the expression of inflammatory-related proteins and cytokines. Molecular docking analysis confirmed the binding effect of 6d with active sites. Conclusion: 6d inhibits NF-κB has a protective effect on arthritis caused by RA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 3,5-Bis(arylidene)-4-piperidone derivatives | |
| 650 | 4 | |a BAPs | |
| 650 | 4 | |a MAPK | |
| 650 | 4 | |a NF-κB | |
| 650 | 4 | |a RA | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 7 | |a Curcumin |2 NLM | |
| 650 | 7 | |a IT942ZTH98 |2 NLM | |
| 650 | 7 | |a NF-kappa B |2 NLM | |
| 650 | 7 | |a Piperidones |2 NLM | |
| 700 | 1 | |a Yan, Weibin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yongjun |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Guige |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Chengbo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 15(2023), 22 vom: 06. Nov., Seite 2051-2064 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:22 |g day:06 |g month:11 |g pages:2051-2064 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2023-0119 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 22 |b 06 |c 11 |h 2051-2064 | ||